Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial Of PSI-938 In Patients With Chronic Hepatitis C
Source: Medical News Today
Thursday 29th July, 2010
Pharmasset, Inc. (Nasdaq: VRUS) announced that safety and pharmacokinetic data from the PSI-352938 ("PSI-938") single ascending dose study support progression to a multiple ascending dose trial with P... ...
Read the full story at
Medical News Today
Email this story to a friend
Have your say on this story
